Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan

Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.

This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications for brain metastases, response durability, toxicity management, and whether the long-standing CLEOPATRA regimen is finally being challenged.

From induction–maintenance strategies to personalized treatment selection, this conversation offers real-world clinical insight into what’s next for HER2+ disease.

🎧 A must-watch for oncologists navigating the next era of HER2-targeted therapy.